Porcine Reproductive & Respiratory Syndrome roadmap:
Vaccines
Roadmap for development of a candidate vaccine for PRRSV
Download PRRSV Vaccine Roadmap3
Rationally attenuated candidates
Dependencies
Development of an attenuated vaccine that doesn’t persist or is excreted
Research Question
- Replicating organisms are likely to give the most appropriate immune response but wild-type virus manipulates the host response. The aim is to reduce the virulence of the organism so that the vaccinated animal can mount a protective immune response
Research Gaps and Challenges
- The generation of GM organisms that are viable but lack virulence and non-protective immune-dominant antigens
- Identification of strains that give the greatest cross protection
- That vaccination prevents excretion of the organism – both the vaccine strain and wild type virus or any combination of the two that may have been generated
Solution Routes
- Monitoring the immune response following immunisation with the various candidates.
- Challenge experiments with the various vaccine candidates, including challenge with other strains
- Identity of cell lines that allow higher production of PRRSV
Dependencies
- The generation of stable genetically modified organisms
- Identity of virulence factors in PRRSV
- Identity of immunomodulators in PRRSV
Projects
What activities are planned or underway?
Immune responses induced by inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine in neonate pigs using different adjuvants
Planned Completion date 01/02/2021
Source Countries:
Netherlands
Additional file 1 of Analysis of ORF5 sequences of Porcine Reproductive and Respiratory Syndrome virus (PRRSV) circulating within swine farms in Costa Rica
Planned Completion date 01/01/2021
Source Countries:
Netherlands